Newsletter | May 14, 2024

05.14.24 -- Nothing To See Here! Just Big Pharma Investments In China


Accelerate cell therapy manufacturing and preserve precious sample material with rapid sterility testing

Read a new application study showing the benefits of rapid sterility testing when managing the fast-paced process and limited shelf life of a cell therapy workflow. Ensure the quality and safety of your final product while minimizing the risk of product loss and delays. Learn how to improve workflow efficiency and maintain the integrity and effectiveness of your cell therapy product now.


Nothing To See Here! Just Big Pharma Investments In China

WuXi AppTec assists U.S.-based biotechs to develop and supply drugs to U.S. patients. Western-based Pharma assists the development of China's industry, the China Communist Party by extension, and patients there. Guess which is under assault? Chief Editor Louis Garguilo tries to figure it all out.

AI And Pharmaceutical Development: WHO Calls For Ethical Framework, Good Governance

The World Health Organization (WHO) recently released a document titled Benefits and risks of using artificial intelligence for pharmaceutical development and delivery describing the ethical issues and governance considerations for using AI in drug discovery, preclinical development, and clinical trials.


In Focus: The C Of CDMO

Delve into the intricacies of a successful CDMO relationship and learn how a collaborative approach built on shared goals and open communication can maximize the potential of your cell therapy program.

The Medicines Of Tomorrow: A Primer On The Gene Editing Landscape

Learn about the distinction between gene therapy and gene editing, as well as the therapeutic potential of CRISPR treatments and the challenges associated with clinical trials and commercialization.

Leveraging A Dynamic Partnership To Revolutionize Nucleic Acid Drugs

Nucleic acid drugs hold the potential to target diseases by harnessing the power of DNA and RNA. Explore how strategic partnerships are enabling the transformative possibilities of these drugs.

The Importance Of CDMO Capacity For Viral Vectors

In this episode of The Business of Biotech, hear experts discuss the importance of increasing specialized CDMO capacity for cell and gene therapy applications.

Viral Vector Manufacturing: Improve Efficiency With A Platform Approach

Learn more about the platform-based scalable suspension process for LVV production and how it is impacting CGTs advancing toward commercialization.

Making The Case For Case Management For Cell And Gene Therapies

It is crucial to ensure that Cell & Gene Therapy (CGT) supply chain risks are mitigated, as well as to have proactive strategies in place to address unforeseen challenges before they become an issue.

Meet An Optimized Suspension-Based Platform Technology

Discover a ready-to-use, suspension-based platform technology for transient transfection of LVVs that eliminates the need to transition from small-scale adherent processes.

How To Apply QbD Principles To Cell And Gene Therapy Release Testing

Review how to develop and use QC assays that can facilitate both product and process understanding and control.


Introducing our new Fill/Finish session! Outsourced Pharma Capacity Update’s new PARTNER WEEK offers an extended schedule and sessions grouped by capability including a day featuring the latest sterile filling, lyophilization, and advanced packaging technologies from CDMOs with current capacity for your manufacturing demands. Secure your spot for this session happening May 20th.


mRNA-LNP CDMO Services

Browse this brochure full of information on manufacturing grades, services, validation, and more that Vernal Biosciences can support.

Looking For Scalability In Clinical Manufacturing?

Looking for scalability in clinical manufacturing? Andelyn Biosciences' current Good Manufacturing Practices (cGMP) Clinical Manufacturing Facility operates according to FDA cGMP Guidelines and with multinational health agencies around the world.

mRNA/saRNA Manufacturing: Accelerate The Path To Clinic

Discover key upstream and downstream considerations for process development for RNA drug substance manufacturing and the parameters that need construct-specific optimization to increase yield and reduce impurities.


Find Your New CDMO At Outsourced Pharma Capacity Update

CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capacities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs.

Connect With Outsourced Pharma: